Literature DB >> 18451234

Profiling tumor-associated autoantibodies for the detection of colon cancer.

Yuliang Ran1, Hai Hu, Zhuan Zhou, Long Yu, Lixin Sun, Jian Pan, Jun Liu, Zhihua Yang.   

Abstract

PURPOSE: The purpose of the present study was to screen the autoantibody signature of colon cancers to develop serum markers for colon cancer detection. EXPERIMENTAL
DESIGN: A phage cDNA expression library of colon cancer was built. The library was sequentially screened by a pool of 10 colon cancer sera, goat antihuman IgG, and a pool of two healthy sera to identify phage-expressed antigens recognized by tumor-associated antibodies. The clones picked out by these screening were subjected to a training set with 24 colon cancer sera and 24 healthy sera. The antigen combination, which got the most satisfactory classification, was tested by an independent set of 24 colon cancer sera with equal number of sera from normal donors. The carcinoembryonic antigen (CEA) level of these sera was detected for the additional classification analysis with or without the antigen combination.
RESULTS: A cDNA expression library consisting of 2 x 10(6) primary clones was prepared. After three turns of screening, 24 antigens recognized by tumor-associated antibodies were picked out for serum marker identification. The training set showed that a six-marker combination got the most satisfactory classification in a logistic regression model; leave-one-out validation achieved 91.7% sensitivity and 91.7% specificity. In a testing set with this marker panel, we correctly predicted 85% of the samples. Although according to CEA level alone, we correctly predicted 75% of the samples with 42% of cancer patients misclassified. When CEA was combined with the six markers, the sensitivity and specificity increased to 91.7% and 95.8%, respectively. The six antigen sequences in the phage display system are relatively short peptides. Only two of them showed homology to known protein sequences.
CONCLUSIONS: Autoantibodies against phage-expressed antigens derived from colon cancer tissues could be used as serum markers for the detection of colon cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18451234     DOI: 10.1158/1078-0432.CCR-07-2021

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  17 in total

1.  Improving seroreactivity-based detection of glioma.

Authors:  Nicole Ludwig; Andreas Keller; Sabrina Heisel; Petra Leidinger; Veronika Klein; Stefanie Rheinheimer; Claudia U Andres; Bernhard Stephan; Wolf-Ingo Steudel; Norbert M Graf; Bernhard Burgeth; Joachim Weickert; Hans-Peter Lenhof; Eckart Meese
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

Review 2.  A systematic review of humoral immune responses against tumor antigens.

Authors:  Miriam Reuschenbach; Magnus von Knebel Doeberitz; Nicolas Wentzensen
Journal:  Cancer Immunol Immunother       Date:  2009-06-28       Impact factor: 6.968

3.  Antibody repertoire profiling using bacterial display identifies reactivity signatures of celiac disease.

Authors:  Bradley N Spatola; Joseph A Murray; Martin Kagnoff; Katri Kaukinen; Patrick S Daugherty
Journal:  Anal Chem       Date:  2012-12-21       Impact factor: 6.986

4.  In vivo amelioration of endogenous antitumor autoantibodies via low-dose P4N through the LTA4H/activin A/BAFF pathway.

Authors:  Yu-Ling Lin; Nu-Man Tsai; Cheng-Hao Hsieh; Shu-Yi Ho; Jung Chang; Hsin-Yi Wu; Ming-Hua Hsu; Chia-Ching Chang; Kuang-Wen Liao; Tiffany L B Jackson; David E Mold; Ru Chih C Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-17       Impact factor: 11.205

Review 5.  Serum tests for colorectal cancer screening.

Authors:  James Creeden; Frank Junker; Sabine Vogel-Ziebolz; Douglas Rex
Journal:  Mol Diagn Ther       Date:  2011-06-01       Impact factor: 4.074

6.  Identification of MST1/STK4 and SULF1 proteins as autoantibody targets for the diagnosis of colorectal cancer by using phage microarrays.

Authors:  Ingrid Babel; Rodrigo Barderas; Ramón Diaz-Uriarte; Víctor Moreno; Adolfo Suarez; María Jesús Fernandez-Aceñero; Ramón Salazar; Gabriel Capellá; J Ignacio Casal
Journal:  Mol Cell Proteomics       Date:  2011-01-12       Impact factor: 5.911

7.  Differential influence of anticancer treatments and angiogenesis on the seric titer of autoantibody used as tumor and metastasis biomarker.

Authors:  Florence Defresne; Caroline Bouzin; Céline Guilbaud; Marc Dieu; Edouard Delaive; Carine Michiels; Martine Raes; Olivier Feron
Journal:  Neoplasia       Date:  2010-07       Impact factor: 5.715

8.  The role of plasma IDO activity as a diagnostic marker of patients with colorectal cancer.

Authors:  M Cavia-Saiz; P Muñiz Rodríguez; B Llorente Ayala; M García-González; M J Coma-Del Corral; C García Girón
Journal:  Mol Biol Rep       Date:  2014-01-17       Impact factor: 2.316

9.  Serum GFAP autoantibody as an ELISA-detectable glioma marker.

Authors:  Ping Wei; Wei Zhang; Liu-Song Yang; Hai-Shi Zhang; Xiao-En Xu; Ying-Hua Jiang; Feng-Ping Huang; Qian Shi
Journal:  Tumour Biol       Date:  2013-04-16

10.  Identification of tumor-associated autoantigens for the diagnosis of colorectal cancer in serum using high density protein microarrays.

Authors:  Ingrid Babel; Rodrigo Barderas; Ramón Díaz-Uriarte; Jorge Luis Martínez-Torrecuadrada; Marta Sánchez-Carbayo; J Ignacio Casal
Journal:  Mol Cell Proteomics       Date:  2009-07-28       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.